c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com
Company profile
Ticker
ARMP
Exchange
Website
CEO
Todd Patrick
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AmpliPhi Biosciences Corp, TARGETED GENETICS CORP /WA/
SEC CIK
Corporate docs
Subsidiaries
C3J Therapeutics, Inc. • C3 Jian, LLC • Biocontrol Limited • AmpliPhi Australia Pty Ltd • Special Phage Holdings Pty Ltd • Special Phage Services Pty Ltd ...
IRS number
911549568
ARMP stock data
Latest filings (excl ownership)
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
22 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
21 Mar 24
8-K
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
4 Mar 24
S-8
Registration of securities for employees
23 Jan 24
S-8
Registration of securities for employees
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
14 Nov 23
UPLOAD
Letter from SEC
13 Nov 23
CORRESP
Correspondence with SEC
7 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 29.78 mm | 29.78 mm | 29.78 mm | 29.78 mm | 29.78 mm | 29.78 mm |
Cash burn (monthly) | (no burn) | 130.00 k | 3.45 mm | 3.47 mm | 3.23 mm | 4.15 mm |
Cash used (since last report) | n/a | 883.25 k | 23.41 mm | 23.58 mm | 21.94 mm | 28.20 mm |
Cash remaining | n/a | 28.90 mm | 6.37 mm | 6.21 mm | 7.84 mm | 1.58 mm |
Runway (months of cash) | n/a | 222.3 | 1.8 | 1.8 | 2.4 | 0.4 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 2 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.24 bn |
Total shares | 66.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
INVA Innoviva | 64.18 mm | $0.00 |
BAC Bank Of America | 634.44 k | $723.27 mm |
Corvesta | 633.94 k | $202.00 k |
Synthetic Genomics | 516.98 k | $2.19 mm |
Bridgeway Capital Management | 193.68 k | $220.80 mm |
Edgewood Management | 100.00 k | $114.00 mm |
Renaissance Technologies | 62.40 k | $71.00 k |
Vanguard | 59.89 k | $68.28 mm |
BLK Blackrock | 24.42 k | $27.83 mm |
Geode Capital Management | 22.46 k | $25.61 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Deborah Birx | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 260,000 |
14 Mar 24 | Deborah Birx | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 240,000 | 811.20 k | 240,000 |
14 Mar 24 | Joseph M Patti | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 54,343 | 183.68 k | 94,009 |
14 Mar 24 | Joseph M Patti | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 39,666 | 134.07 k | 39,666 |
14 Mar 24 | Kramer Robin | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 54,343 | 183.68 k | 94,009 |
14 Mar 24 | Kramer Robin | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 39,666 | 134.07 k | 39,666 |
14 Mar 24 | Todd C. Peterson | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 54,343 | 183.68 k | 94,009 |
14 Mar 24 | Todd C. Peterson | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 39,666 | 134.07 k | 39,666 |
14 Mar 24 | Richard Rychlik | Common Stock | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 10,000 |
14 Mar 24 | Richard Rychlik | Stock Options Common Stock | Grant | Acquire A | No | No | 3.38 | 40,000 | 135.20 k | 40,000 |
News
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
22 Mar 24
Armata Pharmaceuticals Q4 EPS $(0.55) Misses $(0.35) Estimate, Sales $1.53M Beat $860.00K Estimate
21 Mar 24
Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva
4 Mar 24